Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale
The Chinese cancer drug maker’s shares surged on news of approval for its core product, only to return to earth after early investor Temasek exited Key takeaways: • Less than…
RELATED ARTICLES
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US -
Akeso marks profit milestone with swift rights issue
9926.HK
-
FAST NEWS: JW Therapeutics to expand collaboration with 2Seventy Bio
2126.HK
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
